This is a paid press release. Contact the press release distributor directly with any inquiries.
Genflow Biosciences PLC Announces Half-year Financial Report
- GENF.L
- GENFF
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK /ACCESS Newswire/ September 29, 2026 /Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2022.
It is my pleasure to update shareholders of Genflow Biosciences Plc (“Genflow” or the “Company”) on our performance during the first six months of 2026.
As of 30 June 2026, Genflow reached a landmark milestone with the successful completion of SLAB, our lead canine healthspan and sarcopenia clinical trial – a significant achievement that validates our SIRT6 centenarian platform in a real-world aging population and strengthens the Company’s position at the forefront of longevity science. Alongside this milestone, Genflow continued to make strong progress across its programs in both human health and animal health, advancing our mission to extend healthspan through our proprietary SIRT6 centenarian-based gene therapies. These two dimensions of our pipeline are deeply complementary: our human programs target age-related diseases with high unmet need, while our veterinary initiatives allow us to generate translational data, demonstrate safety and feasibility, and explore commercial opportunities in the growing companion animal health sector.
The most notable achievement of the period was the successful completion of SLAB, our comparative, randomized Healthspan and sarcopenia clinical trial in aged Beagle dogs, testing GF-1004, our naked DNA construct. This is a landmark achievement for Genflow, providing strong validation of our SIRT6 cent platform in a real-world aging population and reinforcing our pioneering position in applying SIRT6 cent science to veterinary medicine, complementing our human health programs.
The trial successfully confirmed the safety and tolerability of GF-1004 and generated valuable functional and healthspan data across its endpoints, an encouraging validation of our platform’s real-world applicability. We look forward to presenting full results at the Animal Longevity Summit (ALOS) in Toronto on 2nd October 2026, alongside a scientific manuscript in preparation for peer-reviewed publication. At the same time, we have continued confidential discussions with several leading animal health companies under confidential disclosure agreements, underscoring strong industry interest in innovative approaches to age-related decline in companion animals.
